Evaluation of the immunogenicity of liposome encapsulated HVR1 and NS3 regions of genotype 3 HCV, either singly or in combination by Gupte, Gouri M & Arankalle, Vidya A
RESEARCH Open Access
Evaluation of the immunogenicity of liposome
encapsulated HVR1 and NS3 regions of genotype
3 HCV, either singly or in combination
Gouri M Gupte
1 and Vidya A Arankalle
2*
Abstract
Background: Hepatitis C virus displays a high rate of mutation and exists as a quasispecies in infected patients. In
the absence of an effective universal vaccine, genotype-specific vaccine development represents an alternative. We
have attempted to develop a genotype 3 based, liposome encapsulated HCV vaccine with hypervariable region-1
(HVR1) and non-structural region-3 (NS3) components.
Results: HCV RNA extracted from serum samples of 49 chronically infected patients was PCR amplified to obtain
HVR1 region. These amplified products were cloned to obtain 20 clones per sample in order to identify the
quasispecies pattern. The HVR1 consensus sequence, along with three variants was reverse transcribed to obtain
peptides. The peptides were checked for immunoreactivity individually, as a pool or as a single peptide tetramer
interspersed with four glycine residues. Anti-HCV positivity varied from 42.6% (tetramer) to 92.2% (variant-4) when
115 anti-HCV positive sera representing genotypes 1, 3, 4 and 6 were screened. All the 95 anti-HCV negatives were
scored negative by all antigens. Mice were immunized with different liposome encapsulated or Al(OH)3 adjuvanted
formulations of HVR1 variants and recombinant NS3 protein, and monitored for anti-HVR1 and anti-NS3 antibody
titres, IgG isotypes and antigen specific cytokine levels. A balanced Th1/Th2 isotyping response with high antibody
titres was observed in most of the liposome encapsulated antigen groups. The effect of liposomes and aluminium
hydroxide on the expression of immune response genes was studied using Taqman Low Density Array. Both Th1
(IFN-gamma, Il18) and Th2 (Il4) genes were up regulated in the liposome encapsulated HVR1 variant pool-NS3
combination group. In-vitro binding of the virus to anti-HVR1 antibodies was demonstrated.
Conclusion: The optimum immunogen was identified to be combination of peptides of HVR1 consensus sequence
and its variants along with pNS3 encapsulated in liposomes, which could generate both cellular and humoral immune
responses in mice deserving further evaluation in a suitable cell culture system/non-human primate model.
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Introduction
Hepatitis C virus (HCV), a major causative agent of
chronic hepatitis is distributed worldwide with an esti-
mated 170 million carriers. HCV displays a high rate of
mutation contributed by both host and viral components
[1-4] and exists in infected patients as a quasispecies,
which fluctuate during the course of infection. The
extreme sequence variability among different genotypes
and the global genotype distribution pattern [5] are
major concerns in vaccine development. The observed
absence of protection of chimpanzees against reinfection
with homologous or heterologous strains is noteworthy
[6]. Though the development of an effective vaccine for
HCV has been a challenging task, several attempts have
been made, a few reaching different clinical trial phases
[7]. In the absence of an effective universal vaccine, geno-
type-specific vaccine development represents an alternate
s t r a t e g y .I nI n d i a ,a ne s t i m a t e d1 2t o1 3m i l l i o np e o p l e
are HCV infected [8] with a predominance of genotype 3
(> 70%) [[9], our unpublished data].
* Correspondence: varankalle@yahoo.com
2Hepatitis Group Leader, National Institute of Virology, Microbial
Containment Complex, Sus Road, Pashan, Pune, India 411021
Full list of author information is available at the end of the article
Gupte and Arankalle Virology Journal 2012, 9:74
http://www.virologyj.com/content/9/1/74
© 2012 Gupte and Arankalle; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.The 27 amino acid long N-terminal region of E2 glyco-
protein (amino acids 384-410) termed as hypervariable
region 1 (HVR1), is the most variable region of the whole
HCV polyprotein and containsan e u t r a l i z i n gd e t e r m i -
nant [10-13]. Studies have shown that HVR1 can serve as
B and T cell epitopes and genetic hypervariability is dri-
ven by host’s immune pressure. Various studies have pro-
ven the direct role of anti-HVR1 antibodies in viral
clearance [14-17]. Therefore, we evaluated the HVR1
region for candidate vaccine development. However,
immune response to envelope proteins develops slowly
and achieves only modest titres during primary infection
and use of an additional HCV protein was considered
necessary [18,19]. In this context, non-structural protein-
3 (NS3) eliciting strong humoral and cellular immune
responses was chosen. Importantly, the T-helper immune
response against NS3 is associated with viral clearance
and absence of such response leads to viral persistence
[20,21]. Hence, NS3 may be effectively used for vaccine
development. This study reports our attempts to develop
a genotype-3-based HVR1 and NS3 combination vaccine.
Materials and methods
HVR1 peptide and DNA preparations
Clinical specimens
Serum samples of 49 HCV RNA positive chronic hepati-
tis C patients genotyped earlier and stored at -80°C were
used.
RNA extraction, PCR amplification, sequencing and
cloning
Following RNA extraction (QIAamp viral RNA method,
Qiagen Hilden, Germany) and cDNA generation, HVR1
(1410 to 1610 nt) was amplified using following primers:
SS5 (5’-GGGATATGATGATGAAYTGGT-3’, sense), SS6
(5’-TCTRGGTGSRTAGTGCCAGCA-3’,a n t i s e n s e )f o r
first PCR, and SS7 (5’-TCCATGCARGGCAAYT
TGGGG-3’,s e n s e ) ,S S 8( 5 ’-GGCAGTRCTGTTRATGT
GCCA-3’, antisense) for nested PCR. The 200 bp amplicon
was sequenced using Big Dye Terminator cycle sequencing
technology and ABI3130xl genetic analyzer (Applied Bio-
systems California, USA). For identification of quasispe-
cies, all PCR amplified products were TA cloned using
pGEMT EASY vector system (Promega, WI, USA) accord-
ing to manufacturer’s instructions. On an average, 20
clones were sequenced for every sample. The HVR1
sequences translated to obtain amino acid sequences using
MEGA 3.1 [22], were aligned and the consensus amino
acid at every position of HVR1 region was determined.
HVR1 Peptide/DNA synthesis
Four individual peptide variants were commercially synthe-
sized (Bioconcept, Gurgaon, India). The corresponding
nucleotide sequences of the peptides were synthesized
(Bioresource), amplified and cloned in the pVAX1 vector
(Invitrogen, Life Technologies, Carlsbad). A single peptide
tetramer interspersed with four glycine residues was
obtained from Chromus Biotech, (Bangalore, India). The
consensus sequence (designated as variant 1, STYTTG-
GAAAHTASGLTSLFSPGPKQN) along with three other
variants of the consensus that differed from the consensus
by 5 amino acids (positions 3,8,9,10,11, Variant 2,
STTTTGGSVGRTASGLTSLFSPGPKQN), 3 amino acids
(positions 3,8,9, variant 3, STHTTGGTVAHTASGLTSLF
SPGPKQN) and one amino acid (position 9, variant 4,
STYTTGGAVAHTASGLTSLFSPGPKQN) were used
further ELISA and mice experiments.
ELISA for the evaluation of reactivity of HVR1 peptides
with human sera samples
ELISA was performed according to the protocol described
earlier [23,24] with the following modifications. Maxisorp
Nunc ELISA plates were coated with 1 μg/well peptides
and incubated for 37°C for 1 hour followed by overnight
incubation at 4°C. Anti-HCV positive and anti-HCV nega-
tive human serum samples were added at a dilution of 1:50.
A total of 115 anti-HCV positive and 75 anti-HCV negative
human sera were tested. The genotype distribution of anti-
HCV positive human sera is described in Table 1.
Recombinant NS3 protein/DNA
NS3 (1932 bp) of HCV genotype 3a was amplified using
primers: NS3F1 (5’-ACCTATACGACCACCTAGCGC-
CAA-3’), NS3R1 (5’-CACAATCACAACGCAGCCGAC-3’)
for first PCR, and NS3F2 (5’-GCTTGCGGAGATATTC
TTTGCGGGCT-3’) and NS3R2 (5’-CCAAGCAACACC-
CAGGTGCTG-3) for nested PCR and cloned in pVAX1
and pET15b vectors (Invitrogen, Life technologies, Carls-
bad). The expressed NS3 protein was purified using Pro-
bond purification resin (Invitrogen Life Technologies,
Carlsbad) and gel filtration using HPLC (GE Healthcare).
The immunoreactivity of NS3 protein was confirmed by
western blot using known anti-HCV positive (genotypes
3a, 1b) and anti-HCV negative human sera.
Immunogen formulations
Table 2 lists immunogen formulations and the doses used.
The DNA (nucleotides cloned in pVAX vector) and corre-
sponding protein/peptides (either NS3 and/or HVR1-var-
iant peptides) were encapsulated into liposomes according
to the protocol described earlier [23]. The liposomes
(cadB) were kindly provided by Cadila Pharmaceuticals
(Ahmedabad, India). The antigen formulations were adju-
vanted with Al(OH)3 as described earlier [25].
Mice immunizations
This study was approved by the Institutional Ethical
Committee for animals and experiments were conducted
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cm i c e( 8m i c e / g r o u p )w e r ei mmunized intramuscularly
(100 μl) at 0, 4, and 8 weeks interval with various anti-
gens/combinations and different adjuvants (Table 2). The
immunogens included the four HVR1 variants given indi-
vidually, or as a pool of all four variants or as a tetramer.
Similarly, recombinant NS3 was used in different combi-
nations. Mice were bled before immunization, and at
regular intervals of 2 weeks after first dose and sera were
stored at -20°C till tested.
ELISA for antibodies and isotyping
Recombinant protein based ELISA was performed for
detection and titration of anti-NS3 antibodies as
described earlier with 1 μg/well pNS3 as the coating
antigen [23,24]. For anti-HVR1 antibodies, a similar
Table 1 Performance of HVR1 variants in detecting anti-HCV antibodies
Coating Ag No positive/no tested
Genotype 3 Genotype 1 Genotype 4 Genotype 6 Total
Variant 1 68/85 (80%) 18/25 (72%) 4/4 1/1 91/115 (79.1%)
Variant 2 61/85 (71.7%) 15/25 (60%) 1/4 0/1 77/115 (67%)
Variant 3 74/85 (87%) 24/25 (96%) 2/4 1/1 101/115 (87.8%)
Variant 4 79/85 (92.9%) 22/25 (88%) 4/4 1/1 106/115 (92.2%)
Pool 63/85 (74.1%) 17/25 68%) 2/4 1/1 83/115 (72.2%)
Tetramer 38/85 (44.7%) 10/25 (40%) 0/4 1/1 49/115 (42.6%)
Table 2 Immunogen formulation and doses
Immunogen Dosage Adjuvant used
25 μg peptide + 5 μg corresponding DNA cadB
HVR1 variant1 50 μg peptide + 5 μg corresponding DNA cadB
50 μg peptide + 1 μg pNS3
25 μg peptide + 5 μg corresponding DNA cadB
HVR1 variant2 50 μg peptide + 5 μg corresponding DNA cadB
50 μg peptide + 1 μg pNS3 cadB
25 μg peptide + 5 μg corresponding DNA
HVR1 variant3 50 μg peptide + 5 μg corresponding DNA
50 μg peptide + 1 μg pNS3 cadB
25 μg peptide + 5 μg corresponding DNA cadB
HVR1 variant4 50 μg peptide + 5 μg corresponding DNA cadB
50 μg peptide + 1 μg pNS3
Peptide pool + 5 μg DNA corresponding to each peptide cadB
Peptide pool + 1 μg pNS3 cadB
HVR1 variant pool
(25 μg each peptide)
pool + 1 μg pNS3 Aluminium hydroxide
pool + 1 μg pNS3 no adjuvant
Peptide Pool cadB
Peptide Pool Aluminium hydroxide
Peptide Pool no adjuvant
HVR1 variant tetramer Tetramer 10 μg aluminium hydroxide
Tetramer 10 μg cadB
HVR variant tetramer + pNS3 10 μg tetramer + 1 μg pNS3 aluminium hydroxide
10 μg tetramer + 1 μg pNS3 cadB
1 μg pNS3 cadB
5 μg pNS3 cadB
NS3 1 μg pNS3 + 5 μg corresponding DNA cadB
1 μg pNS3 no adjuvant
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Coating was done at 37°C for 1 hour followed by over-
night incubation at 4°C. Blocking and incubation with
mice sera were done at 37°C for 1 hour. Isotyping was
d o n ea sd e s c r i b e dp r e v i o u s l yb yu s i n gt h er e s p e c t i v e
coating antigens [23].
Cytokine assay
Cytokine assay was performed as described previously
[26]. Cytokines in culture supernatants were measured
using BD Cytometric Bead Array Mouse Th1/Th2 cyto-
kine kit (BD Biosciences, USA).
Taqman low density array
Total RNA extraction and gene expression analysis was
done from frozen spleen samples as described previously
[27]. TLDA card of the mouse immune panel (Applied
Biosystems, UK) was used and run on 7900 HT Fast
Real-time PCR system (Applied Biosystems, UK) Relative
gene expression values were calculated employing com-
parative Ct method using Applied Biosystems relative
quantification (RQ) manager software v1.2. cDNAs from
three phosphate buffered saline immunized mice were
considered as calibrators. Hprt1 gene was used as endo-
genous control. Relative quantification values for each
study group were used to calculate mean RQ values. For
cluster analysis, relative quantification values were log2
transformed and hierarchically clustered with analysis
software (cluster 3.0) [28].
Immune capture RT PCR assay for anti-HVR1 antibodies
The assay was performed as described earlier [29]. RNA
from the captured virus was extracted using Qiagen
viral RNA kit (Qiagen, Hilden, Germany) and diagnostic
PCR was performed using 5’NCR [30].
Statistical analysis
Student-t test and Mann Whitney tests were performed.
SPSS 11.0 software was used for statistical analyses.
Results
Of the 49 genotype-3 patients’ samples used to generate
HVR1 consensus sequence, the subtype distribution was
3a (27, 55.1%), 3b (8, 16.3%), 3e (2, 4.1%), 3f (2, 4.1%), 3 g
(8, 16.3%), 3i (2, 4.1%).
HVR1 consensus sequence
A minimum of 1 and a maximum of 12 quasispecies
were detected. Amino acid positions 2, 6, 7, 10, 19, 20,
23, and 26 were more conserved while 11, 12, 14, 22
and 27 were most variable. The consensus sequence,
variant-1, along with three other variants were evaluated
for immunoreactivity and immunogenicity.
Table 1 compares performance of HVR1 variants in
detecting anti-HCV antibodies in 115 previously identi-
fied anti-HCV positive sera. The percent reactivity for
various HVR1-variants was: 79.1% (Variant-1), 67.0%
(variant-2), 87.8% (variant-3), 92.2% (variant-4), 72.2%
(variant-pool), and 42.6% (variant-tetramer). 75 anti-
HCV negatives were scored negative by all the coating
antigens evaluated.
Anti-HVR1 antibody responses in mice immunized with
individual HVR1-variants
100% seroconversion was observed for all the variants
except variant-2. For variant-1, anti-HVR1 antibody titres
were independent of the dose or addition of pNS3
(Figure 2a). However, after second dose, the antibody
titres in 50 μgp e p t i d e+D N Ag r o u p( p=0 . 0 0 0 )a n d5 0
μg peptide + pNS3 group (p = 0.000) were significantly
higher than 25 μg peptide + DNA group. A similar pat-
tern was observed for variants-3 and 4 (Figure 2c, d).
Antibody titres against variant-1 were significantly higher
than variant-3 (p = 0.000) in the 50 μgp e p t i d e+D N A
groups and 50 μg peptide + pNS3 groups (p = 0.001)
after 2
nd dose. Anti-HVR1 titres were higher for variant-
4t h a nv a r i a n t - 3i n5 0μgp e p t i d e+D N Ag r o u p( p=
0.031) after 2
nd dose. No significant difference in the
anti-HVR1 antibody titres was observed among different
variant groups (p > 0.05) after 3
rd dose, except in variant-
3 and variant-4, 25 μg peptide group (p = 0.009).
Anti-HVR1 antibody responses in mice immunized with
HVR1-variant-pool
In mice immunized with either pool-peptides + DNA, or
pool-peptides + pNS3, 100% seroconversion was noted
after 2
nd dose. No seroconversion was seen when variant-
pool was given alone or with Al(OH)3. Interestingly, 100%
seroconversion was recorded when variant-pool was given
along with CadB. Immunization with DNA alone failed to
produce antibodies. The anti-HVR1 antibody titres of
pHVR1-pool-CadB, pVAX-pHVR-pool-CadB and pHVR1
pool-pNS3-CadB were comparable (p > 0.05). HVR-pool +
pNS3 administered with CadB produced higher antibody
titres than without adjuvant (p = 0.002) (Figure 2e). Addi-
tion of DNA or pNS3 along with peptides did not alter
antibody titres (p > 0.05).
Anti-HVR1 antibody responses in mice immunized with
HVR1-variant-tetramer
100% seroconversion was recorded in all groups after
second dose except when 10 μg tetramer was given with
Al(OH)3 (75% seroconversion after 3 doses). Anti-HVR1-
antibody titres were comparable for tetramer-CadB, tet-
ramer-pNS3-CadB, tetramer-Al(OH)3 and tetramer-
pNS3-Al(OH)3 groups (p > 0.05). Anti-HVR1-antibody
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than tetramer-Al(OH)3 group (p = 0.007). Antibody titres
for tetramer-pNS3-Al(OH)3 and tetramer-pNS3-CadB
groups were comparable after second dose (p > 0.05).
The antibody titres for peptide-pool-pNS3-CadB and tet-
ramer-pNS3-CadB were comparable after third dose (p >
0.05). (Figure 2f)
Anti-NS3p antibody response in mice immunized with
pNS3
Mice immunized with pNS3 without adjuvant served as
controls. 100% seroconversion was recorded when 5 μg
pNS3 was administered with CadB while pNS3-DNA-
CadB and pNS3-1 μg-CadB yielded 87.5% seroconversion;
DNA-CadB alone led to poor response (50%). pNS3 admi-
nistered with individual HVR1-variants, HVR1-variant
pool or tetramer either with CadB or Al(OH)3 led to 100%
seroconversion. Without adjuvant, 66.6% seroconversion
was noted when NS3 was given with HVR1-variant-pool
or tetramer. There was no significant difference in anti-
NS3 antibody titres when pNS3 was given with or without
CadB. The anti-NS3 titres were significantly higher for
pNS3-5 μg-CadB than pNS3-1 μg-CadB group after first
(p = 0.012), second (p = 0.002) and third doses (p = 0.009)
(Figure 2g). Anti-NS3 antibody titres were comparable for
HVR1-variant-pNS3, HVR1-variant-pool-pNS3, and tetra-
mer-pNS3 combinations (p > 0.05). The anti-NS3 titres
Figure 2 Serum anti-HVR1 and anti-NS3 IgG titres (mean ± SE values) at 2 weeks post first, second and third dose in mice immunized
with different antigen formulations. Values are represented as mean log 10 titre ± SE. *p-Value < 0.05 (t-test). a to 2 d: Anti-HVR1 antibody
titres in mice immunized with individual HVR1 variants 1-4 respectively. e: Anti-HVR1 antibody titres in mice immunized with HVR1 variant pool.
f: Anti-HVR1 antibody titres in mice immunized with HVR1 variants tetramer. g, 2 h: Anti-NS3 antibody titres in mice immunized with different
doses of recombinant pNS3, rpNS3 in combination with HVR1 component.
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pNS3 alone (p > 0.05) (Figure 2h).
Antibody isotype profiling
Individual HVR1-variants
Anti-HVR1-IgG antibodies included all the four isotypes
(IgG1, IgG2a, IgG2b and IgG3) suggesting involvement
of both Th1 and Th2 pathways. In variant1-25 μg group,
IgG1 titres were significantly higher than IgG2a titre (p =
0.011) indicating skewing towards Th2 response. How-
ever, with the increase in dose from 25 μgt o5 0μga n d
also with the addition of pNS3, titres against IgG1 and
IgG2a isotypes were comparable suggesting balanced
Th1/Th2 response (p > 0.05) (Figure 3a-1). For variant-3,
50 μg peptide + DNA group showed an increase in IgG2a
titre than IgG1 titre (p = 0.017) indicating Th1 type
response. Titres for other groups of variant-3 were com-
parable (p > 0.05) (Figure 3a-2). When variant-4 was
used as an antigen, for the 25 μgg r o u p ,I g G 1w a s
detected in higher titres than IgG2a (p = 0.047), indica-
tive of Th2 response. IgG isotype titres were comparable
for 50 μgp e p t i d e+D N Aa n d5 0μgp e p t i d e+p N S 3
groups (p > 0.05) suggestive of balanced Th1/Th2
response (Figure 3a-3).
HVR1 variant pool
All the four isotypes IgG1, IgG2a, IgG2b and IgG3 were
detected for the various groups. In HVR1-variant pool-
CadB group, comparable IgG1 and IgG2a titres were
obtained (p > 0.05) indicating a balanced immune
response. In both HVR1-variant pool-DNA-CadB group
(p = 0.007) and HVR1-variant pool-pNS3-CadB group
(p = 0.010), IgG1 titres were significantly higher than
IgG2a titres indicating skewing towards Th2 response
(Figure 3a-4).
HVR1 variant tetramer
All four isotypes (IgG1, IgG2a, IgG2b and IgG3) were
detected indicating involvement of both Th1 and Th2
type immune response. In tetramer-CadB (p = 0.012)
and tetramer-pNS3 CadB (p = 0.021) groups, IgG1 was
detected in higher titres than IgG2a, while IgG1 and
IgG2a titres were comparable when Al(OH)3 was used
along with HVR1-tetramer (p > 0.05) (Figure 3a-5).
Recombinant NS3p
Both cell mediated and humoral response was indicated as
all the four isotypes were detected. When pNS3 was given
along with HVR1-variants-1 or 3 or HVR1-variant-pool-
CadB or tetramer-Al(OH)3, higher IgG1 titres were
detected when compared to IgG2a titres (p = 0.027, 0.003,
0.007, 0.001 respectively). Balanced response was seen in
variant-2-pNS3, variant-4-pNS3 and tetramer-pNS3-CadB
groups with comparable IgG1 and IgG2a titres (p > 0.05).
The pVAX-NS3-variant-pool-CadB group also showed
balanced immune response with comparable IgG1 and
IgG2a titres (p > 0.05) (Figure 3a-6, 3a-7).
Cytokine bead array
For the assessment of the type of immune response
(Th1/Th2/balanced) generated by the different formula-
tions, secretion of specific antigen-stimulated cytokines,
Figure 1 HVR1 amino acid consensus profile obtained from 49 chronically infected hepatitis C patients. On an average, 20 HVR1 clones
were sequenced for each patient. The numbers against each amino acid indicate the number of samples in which that particular amino acid
was present. Consensus sequence is given in bold.
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g/IL-5 (Th2) was determined (Figure 3b). Overall, except
for TNF and IFN-g, induction of other molecules was
not recorded. For HVR1-variant groups, combination
w i t hN S 3d i ds h o ws e c r e t i o no fI F N - ga n dT N F .V a r -
iants 1 and 4 produced higher levels of TNF than IFN-
g. However, variant-3-pNS3 induced high levels of IFN-
g (1348.8 ± 233.8 pg/ml) when compared to TNF (460.9
± 25.6 pg/ml). IL2 was also detected (30.3 ± 1.9 pg/ml).
Addition of corresponding DNA did not influence cyto-
kine stimulation (Figure 3b). In accordance of absence
of antibody response, no cytokines were detected for the
variant-2 group. On the contrary, despite higher anti-
body titres, no cytokines were detected in the tetramer-
group. Immunization with variant pool + NS3 in the
presence/absence of the adjuvant was associated with
the no secretion/secretion of TNF respectively. As far
the response with respect to pNS3 is concerned, var-
iant-1-NS3, Variant-2-NS3, pool-Ns3-CadB, pool-NS3/
tetramer-NS3 without adjuvant and NS3 with/without
adjuvant led to TNF response (Figures 3b). Upon stimu-
lation with pNS3, IFN-g response was noted only with
variant-1 (581.9 ± 130 pg/ml) and 2 (1515.5 ± 143.7 pg/
ml).
Taqman low density array (TLDA)
Upon comparing the genes of the TLDA mouse immune
panel for control groups immunized with PBS, cadB and
aluminium hydroxide with unimmunized control group,
no significant up regulation or down regulation was
noted. This indicated that the adjuvants alone were not
responsible for regulation of the genes.
When pNS3 - HVR1 variant pool was used as a calibra-
tor for pNS3 - HVR1 variant pool - cadB group, the follow-
ing genes were up regulated in the liposome encapsulated
group (fold changes). A difference >/= 2 folds was consid-
ered significant. Th1: IFN-g (3.0), Il18 (2.7), Th2: Il4 (2.7)
Pro-inflammatory: TNF (2.0) Chemokines: Ccl19 (2.6),
Ccl2 (5.0), Ccl3 (4.5), Ccr2 (3.2), Ccr4 (3.9), Ccr7 (3.8),
Cxcl10 (3.1), Cxcr3 (4.1), and Others (Cd19, Cd28, Cd38,
Cd4, Cd40, Cd40Ig, Cd8a, Col4a5, Csf1, Csf2,, Ece1, Edn1,
Gzmb, H2-Eb1, Hmox1, Icos, Ifbkb, Il7, Il15, Prf1, Ptgs2,
Selp, Smad3, Smad7, Socs1, Stat4, Stat6, Tbx21, Tnfsrf18.
Nfkb2). Th1 gene Il2 though not significant, was seen to be
marginally upregulated (1.8). Th2 genes Il13 (8.7), Il5 (7.3),
and chemokine Csf3 (500), were down regulated (Figures
4a, b).
Overall, it was seen that the immune response was
skewed towards Th1 type as suggested by the up regula-
tion of IFN-g, Il18, and Il2 genes. This was further sup-
ported by the up regulation of pro-inflammatory TNF
and chemokine genes (Ccl19, Ccl2, Ccl3, Ccr2, Ccr4,
Ccr7, Cxcl10, Cxcr3). The Th2 genes Il13, Il5 were
down regulated. The up regulation of Il4 suggested gen-
eration of Th2 immune response as well.
On comparing the groups HVR1 variant pool without
adjuvant with HVR1 variant pool given along with cadB
or aluminium hydroxide, there was no significant differ-
ence in the gene profile (data not shown). This further
demonstrates the combined action of NS3 and cadB
that led to the immune response pattern in the pool-
NS3-cadB group as described above.
Figure 3 a Serum anti-HVR1 and anti-NS3 IgG isotype titres at
2 weeks post-third dose in mice immunized with different
antigen formulations at 0, 4 and 8 weeks. Values are represented
as mean log 10 titre ± SE. *p-Value < 0.05 (t-test). a-1 to 3a-3: Serum
antibody isotyping for individual HVR1 variants (variants 1, 3, and 4
respectively). a-4: Serum antibody isotyping for HVR1 variant pool. a-
5: Serum antibody isotyping for HVR1 variant tetramer. a-6, 3a-7:
Serum antibody isotyping for NS3. b: Cytokine profile in
spleenocytes after in vitro stimulation with either HVR1 peptides or
recombinant pNS3 at 2 weeks post-third dose in mice immunized
with different antigen formulations at 0, 4 and 8 weeks. Values are
represented as mean (pg/ml) ± SE. *p-Value ≤ 0.05 (Mann-Whitney
test). b-1 to 3b-3: cytokine profile after stimulation with individual
HVR1 variants1, 3, 4. b-4: cytokine profile after stimulation with HVR1
variant pool. b-5, 3b-6: cytokine profile after stimulation with
recombinant pNS3.
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was used as calibrator. Th1: IFN-g, Il18, Il2. Th2: Il4, Il13, Il15. Pro-inflammatory: Tnf. Chemokines: Ccr2, Ccr4, Ccr7, Cxcl10, Cxcr3, Ccl19, Ccl2,
Ccl3, Csf3. c: Gene up regulation/down regulation (fold change) values for tetramer-NS3-cadB, tetramer-NS3-Al(OH)3, tetramer-NS3 without
adjuvant groups with PBS control as calibrator.
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cadB and tetramer-NS3-aluminium hydroxide groups
were calibrated against PBS, the fas gene was up regu-
lated in all three groups. In tetramer-NS3 without adju-
vant group, cyp1a (333.3 fold) gene and Il9 (10 fold)
were down regulated. In tetramer-pNS3-cadB group
cyp1a (1000 fold) and Il9 (142.9 fold) genes were down
regulated and fas (2.3 fold) and Il6 (2.4 fold) genes were
up regulated (Figure 4c). No significant difference was
recorded for other genes. Il9 was consistently down
regulated in all three groups (tetramer-NS3: 10 fold, tet-
ramer-NS3-cadB: 142.9 fold, tetramer-NS3-Al(OH)3:
1000 fold). Il6 was not significantly altered in the tetra-
mer-NS3 without adjuvant group. However, Il6 expres-
sion was marginally up regulated upon addition of
either cadB (2.4 fold) or Al(OH)3 (2.8 fold). Based on
the expression pattern of these genes, Th1/Th2 immune
response pattern could not be conclusively determined
for tetramer-NS3-cadB, tetramer-NS3- Al(OH)3 or tetra-
mer-NS3 without adjuvant as immunogen groups.
Immune capture-RT PCR
Anti-variant-pool antibodies could bind both genotype
3a and 1b viruses as detected by the immune-capture-
RT PCR (Figure 5).
Discussion
Though the exact mechanisms of protection against HCV
infection remain unclear, association of both humoral
and cellular immune responses have encouraged evalua-
tion of different approaches for vaccine development.
Over the last decade, numerous HCV vaccine approaches
have been assessed in mice and primates. So far, majority
of the recombinant candidate vaccines have been predo-
minantly generated from genotype 1 virus [31,32]. Many
of these vaccine attempts including those reaching clini-
cal trials produced cross-genotypic immune responses
[29,31,33]. Still, the fact remains that the vaccine-geno-
type specific antibodies are mainly produced.
The predominance of genotype 3 in India (> 70%) [9]
led us to attempt to develop a genotype 3 based vaccine.
The two components of our candidate vaccine were the
hyper variable region 1 (HVR1) and non-structural pro-
tein-3 (NS3).
The E2 glycoprotein harbours HVR1, a highly diverse
region of the HCV genome. Taking into consideration
the high mutation rate of the HVR1 region due to host as
well as viral components [34-36], we determined consen-
sus HVR1 sequence based on the genotype-3 HCV
sequences from different parts of India. For this, we used
samples from all available subtypes of genotype 3 in the
frequency at which they were detected in the population
(3a (27, 55.1%), 3b (8, 16.3%), 3e (2, 4.1%), 3f (2, 4.1%),
3 g (8, 16.3%), and 3i (2, 4.1%)).
T h en e x ti s s u et ob ea d d r e s s e dw a st h ep r e s e n c ea n d
distribution of HCV quasispecies in the samples studied.
A shift over time of the minor quasispecies to the most
predominant one has been reported earlier [37]. Under-
standing the degree of variation and proportion of the
different sequences was indeed necessary. For this, the
quasispecies pattern was determined for all the 49
patients by sequencing 20 HVR1 clones obtained from
every patient. The pattern varied from 2 to 14 quasispe-
cies demonstrating degree of sequence variability in dif-
ferent patients and need to consider these variations for
designing appropriate 27 amino acid long HVR1
peptides.
In the HVR1 consensus profile generated during this
study, amino acid positions 2, 6, 7, 10, 19, 20, 23, and 26
were found to be more conserved than the rest (91.8% at
position 2 to 73% at position 10% conservation). Amino
acid positions 11, 12, 14, 22 and 25 were found to be
most variable (77.6% at position 14 to 63.3% at position
11). Importantly, except for position 10, all the other
relatively more conserved amino acids were also present
Figure 5 Lane 1: mouse serum obtained after inoculation with
HVR peptide variant pool (genotype 3a virus). Lane 2: Prebleed
serum tested against genotype 3a virus. Lane 3: Negative control.
Lane 4: mouse serum obtained after inoculation with HVR1 peptide
variant pool (genotype 1b virus). Lane 5: Prebleed serum tested
against genotype 1b virus. Lane 6: Molecular weight marker. Lane 7:
Positive control 250 bp band corresponding to the diagnostic PCR
positive control was detected.
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preference of amino acids in a given position of HVR1
provides information as to the combinations of permissi-
ble mutations in any position of HVR1 [33,38]. This sig-
nificant observation encouraged us to proceed further
and design possible variants of the HVR1 sequence repre-
senting genotype 3 and also expect cross-reactivity with
the other circulating genotypes.
A total of 4 variants were thought to cover the range of
sequence variability. Before assessing the immunogene-
city of the 4 peptide variants in mice, we examined
immunoreactivity with antibodies from 115 anti-HCV
positive patients’ sera infected with different genotypes
(genoytpes 3, 1, 4 and 6). ELISAs were performed using
the peptides individually, as a pool or as a single tetramer
where the individual peptide sequences were used in tan-
dem interspersed with 4 glycine residues. Overall, all the
variants efficiently detected genotype 3 and a substantial
proportion of genotype 1 infected sera (Table 1). Use of
variant pool did not improve ELISA performance, and in
fact, resulted in lower reactivity than the individual var-
iants 1, 3 and 4 probably because of the competitive inhi-
bition. The tetramer exhibited lowest reactivity (42.6%)
with the anti-HCV positive human serum samples when
compared with the peptide pool (72.2%). ELISA results
showed that the HVR1 peptides used exhibited a high
degree of cross-genotypic reactivity and could be taken
forward for the immunogenicity studies. A substantial
proportion (26/40) of anti-HCV positives (genotypes 1, 2,
3 and 4) were earlier shown to be non-reactive with a
peptide polytope comprising of variants of 11 N-terminal
amino acids of HVR1 were used as coating antigens [29].
Our results encouraged us to evaluate the HVR1 consen-
s u sa n di t sv a r i a n t sa sc a n d i d a t ev a c c i n e .M u r i n ea n t i -
body response to HVR1 region was assessed for each
variant individually, pool of all the 4 variants or as a tet-
ramer. The variant-2, though immunoreactive, was not
i m m u n o g e n i ci nm i c e .T h i sv a r i a n td i f f e r e df r o mt h e
consensus sequence by 5 amino acids (positions 3, 8, 9,
10, 11), while the variants 3 and 4 that differed from the
consensus by 3 (positions 3, 8, 9) and 1 (position 9)
amino acids respectively were immunogenic. Probably,
substitutions at four consecutive positions or substitu-
t i o n sa tp o s i t i o n s1 0a n d1 1r e n d e r e dv a r i a n t - 2n o n -
immunogenic. Antibody responses to individual variants
1 ,3a n d4w e r ec o m p a r a b l et ot h eH V R 1v a r i a n tp o o l
and could be detected by all the variants individually,
indicating cross-reactivity in ELISA. The results are in
concordance with Mihailova et al [39], where a combina-
tion of bacterially expressed HVR1 tetramer, core and
NS3 proteins were used as immunogens and high anti-
HVR1 tetramer antibody titres and vigorous lymphopro-
liferative responses were obtained. Similar results were
obtained when HVR1 N-terminal polytope [29], and
HVR1 DNA [40] were used as immunogens.
An NS3 specific CD4+ T cell immune response is
much stronger and more frequently found in patients
who resolve acute hepatitis than in patients who develop
chronic infection and this response may be necessary for
virus clearance [41]. Importantly, several studies have
demonstrated the efficacy of the NS3 region as a vaccine
candidate either singly or in combination with other
HCV proteins [42-46]. In our study 100% antibody sero-
conversion for anti-NS3 antibodies was seen after second
dose. Addition of individual variants, variant pool or tet-
ramer in Cad-B (liposome) yielded optimum and com-
parable antibody titres in mice. The enhanced anti-NS3
response by the addition of HVR1 is of particular advan-
tage as we intended to use combination of HVR1 and
NS3 as vaccine candidates.
As against our earlier observations of enhanced
immune response following encapsulation of proteins
and corresponding DNAs of hepatitis E and B viruses
[25], no advantage was noted with both HVR1 and NS3.
Thus, the phenomenon of enhancement of immuno-
genicity by DNA seems to be immunogen-dependent.
Adjuvanted pNS3 did produce significantly higher anti-
body titres. The effect with reference to adjuvant could be
detected in NS3-HVR1 variant tetramer. 100% seroconver-
sion was noted after third dose for tetramer-pNS3 given
either with cadB or aluminium hydroxide, whereas 66.6%
seroconversion was observed when NS3 was given with
HVR1 variant pool or tetramer without any adjuvant.
On account of the inherent problems of the immuno-
genecity of peptides and recombinant proteins, use of
adjuvants becomes necessary. In view of the crucial role
played by various adjuvants in determining immuno-
genicity,[18,19], we decided to compare, liposomes
(Cad-B) with Al(OH)3, the time-tested adjuvant. In our
lab, liposome was successfully used in the development
of recombinant hepatitis E vaccine as judged by experi-
ments in mice and rhesus monkeys [25,47] as well as
for a recombinant combination vaccine for hepatitis E
and B [25]. Liposome encapsulation did enhance immu-
nogenicity of the HCV antigens [42,48,49]. Though we
were using 27-amino acids peptides as immunogens,
formulations with Cad-B (HVR1 pool alone, HVR1-
pool-NS3 and HVR1-pool + corresponding DNAs)
yielded high antibody titres as compared to low/no anti-
bodies with Al(OH)3. Further, even though the tetramer
induced high antibody titres with different formulations,
the lower efficiency (42.6%, Table 1) in detecting anti-
HCV antibodies in human serum samples argues against
its suitability as a vaccine candidate. Thus, liposome
encapsulated HVR1 peptides emerged as suitable vac-
cine candidate.
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described earlier, it was important to assess the effect of
adjuvants, the individual components and combination of
these immunogens on the antibody response. As far as
the antibody titres against NS3 component is concerned,
addition of individual variants, variant pool or tetramer
in Cad-B yielded optimum titres (Figure 2). Addition of
pNS3 to the peptides did not alter anti-HVR1 antibody
titres significantly (p > 0.05) as compared to the addition
of corresponding DNA (Figure 2). This data strongly sug-
gests utility of HVR1-NS3 combination.
Many reports of vaccine development for hepatitis C
had used ELISPOT, LPA, intracellular staining and chro-
mium release assays to determine the cell mediated
responses against candidate vaccines [29,43,50]. In our
experiments, we used cytokine bead array to determine
the Th1/Th2 response pattern. We also substantiated
this data by serum antibody isotype pattern, an indicator
of the type of immune response obtained. Earlier studies
reported detection of IFN-gamma (Th1 response) and
IL4 (Th2 response) using ELISPOT for NS3 and other
non-structural proteins [51,52]. However, we did not
observe strong T-cell mediated immune response as
judged by the induction of cytokines by antigen-stimu-
lated spleenocytes using CBA. In the cytokine bead array
analysis, activation of both Th1 and Th2 cytokines was
seen though at very low concentrations. This was prob-
ably because mice spleens were harvested at a later stage
(15 days after 3
rd dose). The possibility of higher eleva-
tion in these cytokines at early time points cannot be
ruled out. Incidentally TNF-alpha the pro-inflammatory
cytokine was detected at higher concentrations (to a
maximum of 583.68 ± 51.34 pg/ml).
Isotyping analysis documented involvement of both
Th1 and Th2 type immune responses with NS3 and Th2
with HVR1 component. Variant-1 and 4 with 1 amino
acid substitution behaved similarly i.e., Th2 response
with 25 μg variant + corresponding DNA switching to
balanced Th1/Th2 isotype pattern after the increase of
peptide to 50 μg or addition of 1 μgp N S 3 .T h ee f f e c to f
Al(OH)3 and Cad-B adjuvants on isotype pattern could
be studied for variant-pool and tetramer. Al(OH)3-var-
iant-pool group remained antibody negative while addi-
tion of CadB led to balanced response. With tetramer, Al
(OH)3 gave balanced response while Th2 response was
observed with CadB adjuvant. It has been shown earlier
that the composition of cationic liposomes resulted in a
shift from Th1 to Th2 anti-NS3 antibody response. NS3
DNA given along with DDAB/DOEPC a highly charged
cationic liposome combination was seen to induce Th2
response in comparison to DDAB/EPC liposome-NS3
DNA formulation which induced Th1 response. It was
further hypothesized by Jiao et al [48] that plasmids
adsorbed on muscle cells induced Th2 type of immune
response while those captured directly by APCs would
induce Th1 type of immune response. Thus the type of
response was influenced by the adjuvant used and the
site of injection [48].
We further checked the gene expression profile for
mice immunized with various antigen formulations
either with or without adjuvants using Taqman Low
Density Array (TLDA) in order to confirm the results
obtained in isotyping analysis.
The adjuvants, when given alone without antigens, did
not show significant change in gene profiling when
compared with PBS control, thereby indicating that the
immune response of the antigen was enhanced/modified
because of the adjuvanted antigens. The adjuvants (Al
(OH)3 /CadB) by themselves did not cause alteration in
gene regulation.
Both Th1 and Th2 genes were up regulated indicating a
balanced immune response and its enhancement upon
liposome encapsulation of HVR1 pool-NS3-cadB group.
This conclusion was further supported by serum anti-
body isotypes. The absence of IL5 rise in spleen was
accompanied by the down regulation of the gene.
On comparing HVR1 variant pool without adjuvant and
HVR1 variant pool given either with CadB or aluminium
hydroxide, no significant difference in the gene profile was
recorded. Thus the observed gene profile could be attribu-
ted to the additive effect of NS3, CadB and HVR1 pool. A
similar phenomenon was not observed with the tetramer-
NS3 combinations, indicating that individual peptides
rather than the tetramer could generate better cytokine
response, despite similar antibody titres produced by anti-
HVR1 pool and anti-HVR1 tetramer. This further
strengthens our conclusion that HVR1 variant pool, and
n o tH V R 1t e t r a m e rs h o u l db eu s e df o rf u r t h e rs t u d i e s .
Overall, it was observed that the HVR1 pool-NS3 combi-
nation encapsulated in CadB was the most promising
vaccine candidate to be studied in depth.
In the absence of an easy, efficient and convenient in-
vitro/in-vivo neutralization test system, we performed
the immune capture RT-PCR for the demonstration of
binding of the virus to the antibodies generated against
the HVR1. It is indeed important to note that these
antibodies were able to bind viruses of genotypes 3a and
1b. Whether this binding is indicative of neutralization
cannot be ascertained. Similar results were reported
with HVR1 based polytope vaccine candidate [29].
In conclusion, the combination of peptides of HVR1
consensus sequence and its variants along with pNS3
encapsulated in liposomes could generate both cellular
and humoral immune responses in mice deserving
further evaluation in a suitable cell culture system/non-
human primate model.
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